Thrombin activatable fibrinolysis inhibitor: At the nexus of fibrinolysis and inflammation

Thrombosis Research

Volumn 129, Issue 3, 2012, Pages 314-319

  Colucci, Mario ^a   Semeraro, Nicola ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

bleeding; carboxypeptidase; fibrinolysis; inflammation; thrombin; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTERY THROMBOSIS; BLOOD CLOTTING; FIBRINOLYSIS; HEMOPHILIA; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOPHILIA; VEIN THROMBOSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARBOXYPEPTIDASE U; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION; THROMBIN; THROMBOLYTIC THERAPY; THROMBOMODULIN; THROMBOSIS;

EID: 84857787797     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.10.031     Document Type: Review

References (57)

1. L. Bajzar Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway Arterioscler Thromb Vasc Biol 20 2000 2511 2518
2. E. Heylen, J. Willemse, and D. Hendriks An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis Front Biosci 17 2011 2427 2450
3. L.O. Mosnier, and B.N. Bouma Regulation of Fibrinolysis by Thrombin Activatable Fibrinolysis Inhibitor, an Unstable Carboxypeptidase B That Unites the Pathways of Coagulation and Fibrinolysis Arterioscler Thromb Vasc Biol 26 2006 2445 2453 (Pubitemid 44607464)
4. J. Morser, E.C. Gabazza, T. Myles, and L.L. Leung What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse? J Thromb Haemost 8 2010 868 876
5. L.O. Mosnier, P. Buijtenhuijs, P.F. Marx, J.C. Meijers, and B.N. Bouma Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets Blood 101 2003 4844 4846 (Pubitemid 36857744)
6. S.L. Schadinger, J.H. Lin, M. Garand, and M.B. Boffa Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets J Thromb Haemost 8 2010 2523 2529
7. J. Leurs, and D. Hendriks Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease Thromb Haemost 94 2005 471 487 (Pubitemid 41300839)
8. M. Schneider, M. Boffa, R. Stewart, M. Rahman, M. Koschinsky, and M. Nesheim Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme J Biol Chem 277 2002 1021 1030 (Pubitemid 34968847)
9. B. Wiman, and D. Collen Molecular mechanism of physiological fibrinolysis Nature 272 1978 549 550 (Pubitemid 8312311)
10. J. Leurs, V. Nerme, Y. Sim, and D. Hendriks Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism J Thromb Haemost 2 2004 416 423 (Pubitemid 40185652)
11. C.M. Swaisgood, D. Schmitt, D. Eaton, and E.F. Plow In vivo regulation of plasminogen function by plasma carboxypeptidase B J Clin Invest 110 2002 1275 1282 (Pubitemid 35291121)
12. R.A. Skidgel, and E.G. Erdos Structure and function of human plasma carboxypeptidase N, the anaphylatoxin inactivator Int Immunopharmacol 7 2007 1888 1899 (Pubitemid 350138511)
13. J.B. Walker, T.M. Binette, M. Mackova, G.R. Lambkin, L. Mitchell, and L. Bajzar Proteolytic cleavage of carboxypeptidase N markedly increases its antifibrinolytic activity J Thromb Haemost 6 2008 848 855 (Pubitemid 351524547)
14. C.T. Esmon Inflammation and the activated protein C anticoagulant pathway Semin Thromb Hemost 32 Suppl. 1 2006 49 60
15. L.O. Mosnier, J.C. Meijers, and B.N. Bouma Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin Thromb Haemost 85 2001 5 11 (Pubitemid 32050935)
16. D.M. Monroe, and M. Hoffman What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 26 2006 41 48 (Pubitemid 43732226)
17. P.A. Von dem Borne, L. Bajzar, J.C. Meijers, M.E. Nesheim, and B.N. Bouma Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis J Clin Invest 99 1997 2323 2327 (Pubitemid 27227707)
18. M. Colucci, J.A. Paramo, and D. Collen Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo J Lab Clin Med 108 1986 53 59 (Pubitemid 16070871)
19. E. Vercauteren, J. Emmerechts, M. Peeters, M.F. Hoylaerts, P.J. Declerck, and A. Gils Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model Blood 117 2011 4615 4622
20. J. Leurs, B.M. Wissing, V. Nerme, K. Schatteman, P. Bjorquist, and D. Hendriks Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma Thromb Haemost 89 2003 264 271 (Pubitemid 36227277)
21. T.M. Binette, F.B. Taylor Jr., G. Peer, and L. Bajzar Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon Blood 110 2007 3168 3175 (Pubitemid 350106308)
22. A.S. Wolberg Thrombin generation and fibrin clot structure Blood Rev 21 2007 131 142 (Pubitemid 46541695)
23. P.N. Walsh, C.R. Rizza, J.M. Matthews, J. Eipe, P.B. Kernoff, and M.D. Coles Epsilon-Aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial Br J Haematol 20 1971 463 475
24. G.J. Broze Jr., and D.A. Higuchi Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma Blood 88 1996 3815 3823 (Pubitemid 26383103)
25. L.O. Mosnier, T. Lisman, H.M. van den Berg, H.K. Nieuwenhuis, J.C. Meijers, and B.N. Bouma The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration Thromb Haemost 86 2001 1035 1039 (Pubitemid 32975830)
26. A.S. Wolberg, G.A. Allen, D.M. Monroe, U. Hedner, H.R. Roberts, and M. Hoffman High dose factor VIIa improves clot structure and stability in a model of haemophilia B Br J Haematol 131 2005 645 655 (Pubitemid 43899632)
27. T. Lisman, P.G. de Groot, T. Lambert, R. Rojkjaer, and E. Persson Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A J Thromb Haemost 1 2003 2175 2178
28. L. Bajzar, M.E. Nesheim, and P.B. Tracy The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent Blood 88 1996 2093 2100 (Pubitemid 26307911)
29. T. Lisman, J. Adelmeijer, H.K. Nieuwenhuis, and P.G. de Groot Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor Blood Coagul Fibrinolysis 14 2003 557 562 (Pubitemid 37083171)
30. C.T. Ammollo, F. Semeraro, N. Semeraro, and M. Colucci The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins Thromb Haemost 101 2009 782 785
31. V.G. Nielsen, and J.K. Kirklin Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII Blood Coagul Fibrinolysis 19 2008 793 800
32. C.T. Ammollo, F. Semeraro, F. Incampo, N. Semeraro, and M. Colucci Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor J Thromb Haemost 8 2010 790 798
33. M.M. Samama, L. Le Flem, C. Guinet, G. Gerotziafas, and F. Depasse Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants J Thromb Haemost 5 2007 2554 2556 (Pubitemid 350154370)
34. E. Perzborn, and M. Harwardt Direct Thrombin Inhibitors, but Not Factor Xa Inhibitors, Enhance Thrombin Formation in Human Plasma by Interfering with the Thrombin-Thrombomodulin-Protein C System Blood (ASH Annual Meeting Abstracts) 112 2008 528
35. M. Colucci, B.M. Binetti, A. Tripodi, V. Chantarangkul, and N. Semeraro Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism Blood 103 2004 2157 2161 (Pubitemid 38326233)
36. L. Bajzar, M. Kalafatis, P. Simioni, and P.B. Tracy An antifibrinolytic mechanism describing the prothrombotic effect associated with factor VLeiden J Biol Chem 271 1996 22949 22952 (Pubitemid 26314721)
37. M. Colucci, P. Simioni, D. Piro, P. Prandoni, A. Pagnan, and N. Semeraro An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia Haematologica 88 2003 1383 1389 (Pubitemid 38029722)
38. M. Colucci, F. Incampo, C. Carrieri, L. La Grasta, and N. Semeraro Antifibrinolytic activity of thrombin and TAFIa generated outside the clot. Do anticoagulants enhance clot lysis? J Thromb Haemost 9 s2 2011 P-WE-253
39. T. Lisman, F.W. Leebeek, L.O. Mosnier, B.N. Bouma, J.C. Meijers, and H.L. Janssen Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis Gastroenterology 121 2001 131 139 (Pubitemid 32591523)
40. J. Duchemin, B. Pan-Petesch, B. Arnaud, M.T. Blouch, and J.F. Abgrall Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma Thromb Haemost 99 2008 767 773 (Pubitemid 351694233)
41. Y. Dargaud, M.C. Trzeciak, J.C. Bordet, J. Ninet, and C. Negrier Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype Thromb Haemost 96 2006 562 567 (Pubitemid 44782534)
42. J.L. Willemse, E. Heylen, M.E. Nesheim, and D.F. Hendriks Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy? J Thromb Haemost 7 2009 1962 1971
43. Y.X. Wang, V. da Cunha, J. Vincelette, L. Zhao, M. Nagashima, and K. Kawai A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis Thromb Haemost 97 2007 54 61 (Pubitemid 46242387)
44. E. Bird, J. Tamura, J.S. Bostwick, T.E. Steinbacher, A. Stewart, and Y. Liu Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats? Thromb Res 120 2007 549 558 (Pubitemid 47094912)
45. J.L. Willemse, and D.F. Hendriks A role for procarboxypepidase U (TAFI) in thrombosis Front Biosci 12 2007 1973 1987 (Pubitemid 46846821)
46. G. Schultz, M.M. Tedesco, E. Sho, T. Nishimura, S. Sharif, and X. Du Enhanced Abdominal Aortic Aneurysm Formation in Thrombin-Activatable Procarboxypeptidase B-Deficient Mice Arterioscler Thromb Vasc Biol 30 2010 1363 1370
47. R. Renckens, J.J. Roelofs, S.A. ter Horst, C. van 't Veer, S.R. Havik, and S. Florquin Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice J Immunol 175 2005 6764 6771 (Pubitemid 41598921)
48. Foley JH, Nesheim ME, Rivard GE, Brummel-Ziedins KE, in press. Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A. Haemophilia. 20 SEP 2011 doi:10.1111/j.1365-2516.2011.02648.x.
49. C. Carrieri, R. Galasso, F. Semeraro, C.T. Ammollo, N. Semeraro, and M. Colucci The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood J Thromb Haemost 9 2011 154 162
50. D.B. Cines, and J.B. Bussel How I treat idiopathic thrombocytopenic purpura (ITP) Blood 106 2005 2244 2251 (Pubitemid 41510792)
51. I. Juhan-Vague, and P.E. Morange Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME Study J Thromb Haemost 1 2003 2243 2244
52. M.E. Meltzer, C.J. Doggen, P.G. de Groot, F.R. Rosendaal, and T. Lisman Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men Br J Haematol 145 2009 121 127
53. E. Ceresa, E. Brouwers, M. Peeters, C. Jern, P.J. Declerck, and A. Gils Development of ELISAs measuring the extent of TAFI activation Arterioscler Thromb Vasc Biol 26 2006 423 428 (Pubitemid 43732210)
54. D.A. Tregouet, R. Schnabel, M.C. Alessi, T. Godefroy, P.J. Declerck, and V. Nicaud Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study J Thromb Haemost 7 2009 49 57
55. C. Ladenvall, A. Gils, K. Jood, C. Blomstrand, P.J. Declerck, and C. Jern Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation Arterioscler Thromb Vasc Biol 27 2007 955 962 (Pubitemid 46606731)
56. E.L. de Bruijne, A. Gils, A.H. Guimaraes, D.W. Dippel, J.W. Deckers, and A.H. van den Meiracker The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study J Thromb Haemost 7 2009 919 927
57. H. Eriksson, JE, P.M. Sandset, U. Wall, M. Andersson, and V. Nerme CPU inhibition with AZD9684: profibrinolytic effects in acute PE patients J Thromb Haemost 5 s2 2007 P-S-367